Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CoreA HER2-targeted NK cell chemoimmunotherapy
- Development stage
- Preclinical
- Lead developer
- CoreA Therapeutics
- Modality
- Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
CoreA Therapeutics is developing a HER2-targeted chemoimmunotherapy candidate utilizing its proprietary Targeted Chemo-Immunotherapy (TCI) platform. This therapeutic approach involves engineering natural killer (NK) cells to function as both active immune effectors and delivery vehicles for cytotoxic payloads, effectively combining the mechanisms of cell therapy and antibody-drug conjugates (ADCs). The therapy is designed to target the Human Epidermal Growth Factor Receptor 2 (HER2) on solid tumors. By loading NK cells with a chemotherapeutic payload, the treatment aims to deliver high concentrations of the drug directly to the tumor site while simultaneously leveraging the NK cells' innate ability to recognize and lyse malignant cells, potentially enhancing efficacy in the immunosuppressive microenvironment of solid tumors.
- Other names
- CoreA HER2-targeted NK cell therapyCoreA HER2-ADC-NK cell therapyHER2-targeted Targeted Chemo-ImmunotherapyHER-2-targeted Targeted Chemo-ImmunotherapyHER 2-targeted Targeted Chemo-ImmunotherapyCoreA HER2-TCI
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on CoreA HER2-targeted NK cell chemoimmunotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CoreA HER2-targeted NK cell chemoimmunotherapy.